Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) has been assigned a $14.00 target price by analysts at Canaccord Genuity in a note issued to investors on Thursday. The firm presently has a “hold” rating on the specialty pharmaceutical company’s stock. Canaccord Genuity’s target price suggests a potential downside of 0.50% from the company’s previous close.

VRX has been the subject of a number of other reports. J P Morgan Chase & Co set a $10.00 price target on Valeant Pharmaceuticals International and gave the company a “hold” rating in a report on Monday, July 17th. BTIG Research reaffirmed a “neutral” rating on shares of Valeant Pharmaceuticals International in a report on Wednesday, May 10th. Mizuho reaffirmed an “underperform” rating and set a $8.00 price target (down from $9.00) on shares of Valeant Pharmaceuticals International in a report on Monday, April 17th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Valeant Pharmaceuticals International in a report on Wednesday, May 10th. Finally, Guggenheim assumed coverage on Valeant Pharmaceuticals International in a report on Saturday, June 17th. They set a “buy” rating and a $18.00 price target for the company. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Valeant Pharmaceuticals International has an average rating of “Hold” and an average price target of $17.26.

Valeant Pharmaceuticals International (NYSE VRX) opened at 14.07 on Thursday. Valeant Pharmaceuticals International has a 52 week low of $8.31 and a 52 week high of $32.74. The company’s 50-day moving average price is $16.44 and its 200-day moving average price is $13.39. The company’s market capitalization is $4.90 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 58.02% and a negative net margin of 14.96%. The firm had revenue of $2.23 billion during the quarter, compared to analysts’ expectations of $2.23 billion. During the same period last year, the firm posted ($0.88) EPS. The business’s revenue was down 7.7% on a year-over-year basis. On average, equities analysts forecast that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Canaccord Genuity Analysts Give Valeant Pharmaceuticals International, Inc. (NYSE:VRX) a $14.00 Price Target” was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/canaccord-genuity-analysts-give-valeant-pharmaceuticals-international-inc-nysevrx-a-14-00-price-target/1467110.html.

Hedge funds have recently modified their holdings of the stock. Gruss & Co. Inc. bought a new stake in Valeant Pharmaceuticals International during the first quarter worth about $104,000. Financial Architects Inc increased its stake in Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares in the last quarter. Harbor Advisors LLC bought a new stake in Valeant Pharmaceuticals International during the first quarter worth about $110,000. WMS Partners LLC bought a new stake in Valeant Pharmaceuticals International during the first quarter worth about $116,000. Finally, Brave Asset Management Inc. bought a new stake in Valeant Pharmaceuticals International during the first quarter worth about $119,000. Institutional investors own 51.14% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.